Jacques FellayJacques Fellay is a medical scientist with expertise in infectious diseases and human genomics. He obtained his MD from the University of Lausanne in 2002 and his PhD from University of Utrecht. After a clinical training in infectious diseases in Switzerland and a 4-years postdoctoral fellowship at Duke University, he joined the EPFL in April 2011 with an SNF Professorship.
On top of his EPFL affiliation, Jacques is also Head of Precision Medicine at the University Hospital (CHUV) in Lausanne, Group Leader at the Swiss Institute of Bioinformatics, and Co-director of the Health2030 Genome Center at Campus Biotech in Geneva.
Olivier SchneiderAprès une thèse en physique des particules à l'Université de Lausanne, soutenue en 1989, Olivier Schneider rejoint le LBL, Lawrence Berkeley Laboratory (Californie), pour travailler sur l'expérience CDF au Tevatron de Fermilab (Illinois), d'abord au bénéfice d'une bourse de chercher débutant du Fonds National Suisse pour la Recherche Scientifique, puis comme post-doc au LBL. Il participe à la construction et à la mise en service du premier détecteur de vertex au silicium fontionnant avec succès auprès d'un collisionneur hadronique, détecteur qui a permis la découverte du sixième quark, appelé "top". Dès 1994, il revient en Europe et participe à l'expérience ALEPH au grand collisionneur électron-positon du CERN (Genève), comme boursier puis comme titulaire d'un poste de chercheur au CERN. Il se spécialise en physique des saveurs lourdes. En 1998, il est nommé professeur associé à l'Université de Lausanne, puis professeur extraordinaire à l'EPFL en 2003, et enfin professeur ordinaire à l'EPFL en 2010. Ayant participé depuis 1997 à la préparation de l'expérience LHCb au collisionneur LHC du CERN, entrée en fonction à fin 2009, il en analyse maintenant les données. Il contribue aussi depuis 2001 à l'exploitation des données enregistrées par l'expérience Belle au laboratoire KEK (Tsukuba, Japon). Ces deux expériences étudient principalement les désintégrations de hadrons contenant un quark b, ainsi que la violation de CP, c'est-à-dire le non-respect de la symétrie entre matière et antimatière.
Hilal Lashuel2012-2013 Visiting Professor, Standford University. Stanford School of Medicine
2011- Associate Professor of Life Sciences-Brain Mind Institute-EPFL
Dir. Laboratory of Chemical Biology of Neurodegeneration
2005-2011 Assistant Professor of Life Sciences-Brain Mind Institute-EPFL
Dir. Laboratory of Molecular Neurobiology and Neuroproteomics
2005-2008 Director- EPFL Proteomic Core Facility
2002-2004 Instructor of Neurology- Harvard Medical School and Brigham and Women's
Hospital
2001-2002 Sabbatical Fellow- Laboratory for Drug Discovery in Neurodegeneration
Harvard Medical School,
2001-2002 Post-doctoral Fellow- Center for Neurologic Diseases
Harvard Medical School and Brigham and Women's Hospital
Advisor- Prof. Peter T. Lansbury
2000-2001 Research Scientist, The Picower Institute for Medical Research, Great Neck
New York
1994-2000 PhD Student; Texas A&M University and the Scripps Research Institute
Advisor- Prof. Jeffery W. Kelly
1990-1994 B.S. City University of New York, Brooklyn College
Dr. Hilal A. Lashuel received his B.Sc. degree in chemistry from the City University of New York in 1994 and completed his doctoral studies at Texas A&M University and the Scripps Research Institute in 2000. After obtaining his doctoral degree, he became a research fellow at the Picower Institute for Medical Research in Long Island New York. In 2001, he moved to Harvard Medical School and the Brigham and Women's Hospital as a research fellow in the Center for Neurologic Diseases and was later promoted to an instructor in neurology at Harvard Medical School. During his tenure (2001-2004) at Harvard Medical School his work focused on understanding the mechanisms of protein misfolding and fibrillogenesis and the role of these processes in the pathogenesis of Parkinson's and Alzheimer's disease. In 2005 Dr. Lashuel moved Switzerland to join the Brain Mind Institute at the Swiss Federal Institute of Technology Lausanne as a tenure-track assistant professor in neurosciences. Currently, Dr. Lashuel is an associate professor of life sciences and the director of the laboratory of molecular and chemical biology of neurodegeneration. (http://lashuel-lab.epfl.ch/).
Research efforts in the Lashuels laboratory focus on understanding the molecular mechanisms of neurodegeneration and developing novel strategies to diagnose and treat neurodegenerative diseases such as Alzheimers and Parkinsons disease. Research in the Lashuel lab is funded by several international funding agencies and foundations, including the Swiss National Science Foundation, European FP7 program (Marie Curie and ERC grants), Human Science Frontiers, Strauss Foundation, Cure the Huntingtons disease foundation and Michael J Fox foundation and is supported by collaborations with pharmaceutical and biotech companies (http://lashuel-lab.epfl.ch/page-50538-en.html), Nestle, Merck-Serono, AC Immune and Johnson and Johnson.
Dr. Lashuels research has resulted in the characterization of novel quaternary structure intermediates on the amyloid pathway, identification of potential therapeutic targets, and new hypotheses concerning the mechanisms of pathogenesis in Alzheimers disease, Parkinsons disease and related disorders. Dr. Lashuel scientific contribution to this field includes i) more than100 publications in major peer reviewed journals including Nature journals, Cell, PNAS, JBC, J. Neuroscience JACS, and Angewandtie Chemie; ii) three patents on novel strategies for preventing protein aggregation and treating autoimmune and inflammatory diseases; iii) more than 150 invited lectures since 2002 and more than 5500 citations (7800 citation-Google Scholar) since 1996. Dr. Lashuel has received several pre-doctoral and post-doctoral awards and fellowships and was the recipient of two prestigious awards given to young investigators; Human Science Frontiers young investigator research award and the European Research Council (ERC) starting independent researcher grant and the ERC proof of concept award (2013) These awards provide more than $2.5 Million to Dr. Lashuel to translate some of his ideas and projects into novel strategies for diagnosing and treating neurodegenerative diseases such as Alzheimers and Parkinsons disease. Dr. Lashuel has chaired and co-organized several international conferences and serves as an academic editor for PLoS ONE, an associate editor for frontiers of molecular neuroscience, member of the Editorial advisory board of ChemBioChem and ad hoc reviewer for several international scientific journals and funding agencies. Stewart ColeProfessor Stewart Cole is an international authority in bacterial molecular-genetics and genomics. He has made outstanding contributions in several fields including: bacterial anaerobic electron transport; genome analysis of retroviruses and papillomaviruses; antibiotic resistance mechanisms; and the molecular microbiology of toxigenic clostridia. His studies on isoniazid and multidrug resistance in Mycobacterium tuberculosis, together with his pioneering work on the pathogenicity, evolution and genomics of the tubercle and leprosy bacilli, have made him an undisputed leader in the field of mycobacterial research. The findings of his research are of direct relevance to public health and disease-control in both the developing world and the industrialised nations. He has published over 250 scientific papers and review articles, and holds many patents.
Jean-Philippe ThiranJean-Philippe Thiran was born in Namur, Belgium, in August 1970. He received the Electrical Engineering degree and the PhD degree from the Université catholique de Louvain (UCL), Louvain-la-Neuve, Belgium, in 1993 and 1997, respectively. From 1993 to 1997, he was the co-ordinator of the medical image analysis group of the Communications and Remote Sensing Laboratory at UCL, mainly working on medical image analysis. Dr Jean-Philippe Thiran joined the Signal Processing Institute (ITS) of the Swiss Federal Institute of Technology (EPFL), Lausanne, Switzerland, in February 1998 as a senior lecturer. He was promoted to Assistant Professor in 2004, to Associate Professor in 2011 and is now a Full Professor since 2020. He also holds a 20% position at the Department of Radiology of the University of Lausanne (UNIL) and of the Lausanne University Hospital (CHUV) as Associate Professor ad personam. Dr Thiran's current scientific interests include
Computational medical imaging: acquisition, reconstruction and analysis of imaging data, with emphasis on regularized linear inverse problems (compressed sensing, convex optimization). Applications to medical imaging: diffusion MRI, ultrasound imaging, inverse planning in radiotherapy, etc.Computer vision & machine learning: image and video analysis, with application to facial expression recognition, eye tracking, lip reading, industrial inspection, medical image analysis, etc.
Touradj EbrahimiTouradj EBRAHIMI received his M.Sc. and Ph.D., both in Electrical Engineering, from the Swiss Federal Institute of Technology (EPFL), Lausanne, Switzerland, in 1989 and 1992 respectively. In 1993, he was a research engineer at the Corporate Research Laboratories of Sony Corporation in Tokyo, where he conducted research on advanced video compression techniques for storage applications. In 1994, he served as a research consultant at AT&T Bell Laboratories working on very low bitrate video coding. He is currently Professor at EPFL heading its Multimedia Signal Processing Group. He is also the Convenor of JPEG standardization Committee. He was also adjunct Professor with the Center of Quantifiable Quality of Service at Norwegian University of Science and Technology (NTNU)between 2008 and 2012.
Prof. Ebrahimi has been the recipient of various distinctions and awards, such as the IEEE and Swiss national ASE award, the SNF-PROFILE grant for advanced researchers, Four ISO-Certificates for key contributions to MPEG-4 and JPEG 2000, and the best paper award of IEEE Trans. on Consumer Electronics . He became a Fellow of the international society for optical engineering (SPIE) in 2003. Prof. Ebrahimi has initiated more than two dozen National, European and International cooperation projects with leading companies and research institutes around the world. He is a co-founder of Genista SA, a high-tech start-up company in the field of multimedia quality metrics. In 2002, he founded Emitall SA, start-up active in the area of media security and surveillance. In 2005, he founded EMITALL Surveillance SA, a start-up active in the field of privacy and protection. He is or has been associate Editor with various IEEE, SPIE, and EURASIP journals, such as IEEE Signal Processing Magazine, IEEE Trans. on Image Processing, IEEE Trans. on Multimedia, EURASIP Image Communication Journal, EURASIP Journal of Applied Signal Processing, SPIE Optical Engineering Magazine. Prof. Ebrahimi is a member of Scientific Advisory Board of various start-up and established companies in the general field of Information Technology. He has served as Scientific Expert and Evaluator for Research Funding Agencies such as those of European Commission, The Greek Ministry of Development, The Austrian National Foundation for Scientific Research, The Portuguese Science Foundation, as well as a number of Venture Capital Companies active in the field of Information Technologies and Communication Systems. His research interests include still, moving, and 3D image processing and coding, visual information security (rights protection, watermarking, authentication, data integrity, steganography), new media, and human computer interfaces (smart vision, brain computer interface).
He is the author or the co-author of more than 200 research publications, and holds 14 patents. Prof. Ebrahimi is a member of IEEE, SPIE, ACM and IS&T.
See the URL below for more details:
http://mmspl.epfl.ch 